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Heart cells are the unitary elements that define cardiac function and disease. The recent identification of
distinct families of cardiovascular progenitor cells begins to build a foundation for our understanding of
the developmental logic of human cardiovascular disease, and also points to new approaches to arrest
and/or reverse its progression, a major goal of regenerative medicine. In this review, we highlight recent
clarifications, revisions, and advances in our understanding of the many lives of a heart cell, with a primary
focus on the emerging links between cardiogenesis and heart stem cell biology.‘‘Almost everything offered today for the treatment of
heart disease is at the level of [halfway] technology.when
enough has been learned to know what really goes wrong
in heart disease, one ought to be in a position to figure out
ways to prevent or reverse the process.’’
—Lewis Thomas, ‘‘The Lives of a Cell’’ (1974)
Reversing the process of heart disease progression is a funda-
mental tenet of cardiovascular regenerative medicine. As noted
by Lewis Thomas over three decades ago, this will undoubtedly
require an in-depth knowledge of not only the genes and molec-
ular pathways that are linked to cardiovascular disease, but ulti-
mately an identification of how these go awry in specific subsets
of heart cells. The heart is a mosaic of many types of differenti-
ated cells, including pacemaker, valvular, arterial and venous
smooth muscle, endothelial cells, autonomic ganglia, and dis-
crete atrial and ventricular myocytes. How is this diversity gener-
ated? Is there a common ancestor that gives rise to these diverse
cell types? Can heart diseases that appear in the adult relate to
primary, early effects on the renewal or directed differentiation of
the fetal heart progenitor pool? What are the intermediates that
link these early progenitors with differentiated cell types? Do
any of these cells persist after birth, and if so could they play
a role in either in vivo or ex vivo regeneration of specific heart
components? Answering these questions lies at the core of
modern regenerative medicine for cardiovascular disease. This
review will highlight recent clarifications, revisions, and ad-
vances in our understanding of the many lives of a heart cell,
with a primary focus on the emerging links between cardiogene-
sis and heart stem cell biology.
A Panoply of Potential Heart Progenitors
To the casual observer, there would seem to be no shortage of
potential sources of heart stem cells and related progenitors.
Over the past few years, numerous reports of heart progenitors
from diverse fetal and adult tissue sources outside the cardio-
vascular system have surfaced (for review, see Franco et al.,
2007), ranging from skeletal muscle, hematopoietic, and bone320 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.marrow mesenchymal cells (Figure 1), to amniotic fluid, placenta,
testes, and adipose tissue (Figure 2) (Franco et al., 2007). For the
most part, these studies have been based on the long-term cul-
ture of cells dispersed from intact tissue sources, raising the is-
sue of phenotypic drift of the cells that arise from a tissue culture
artifact. The issue of culture-dependent conditions has resur-
faced given the difficulty of reproducing many of the published
findings, raising the need for a more standardized set of criteria
to justify the claim that an authentic heart stem or progenitor cell
has been discovered. Because there have been no reports to
date of cell surface determinants that are specific for heart
stem cells or progenitors, most of these studies employ mixed
cell populations as starting material and rely on the emergence
of phenotypic features of cardiovascular cell types that include
sarcomere formation, expression of cardiovascular markers,
and in certain cases physiological functional readouts (for a de-
tailed listing see Figures 1 and 2) (Alvarez-Dolado et al., 2003;
Baba et al., 2007; Chiavegato et al., 2007; De Coppi et al.,
2007; Gaustad et al., 2004; Guan et al., 2006; Jackson
et al., 2001; Makino et al., 1999; Okamoto et al., 2007; Orlic
et al., 2001; Planat-Benard et al., 2004; Rangappa et al., 2003;
Reinecke et al., 2000; Rota et al., 2007; Toma et al., 2002;
Ventura et al., 2007; Winitsky et al., 2005). However, these
parameters may not be sufficient to define a bona fide heart pro-
genitor or stem cell. In addition, there are several limitations to
the use of these populations for cardiac regenerative medicine
purposes, such as their low frequency of cardiac differentiation,
the possibility of cell fusion with resident cardiomyocytes, and
electrical coupling defects observed after transplantation
(Balsam et al., 2004; Murry et al., 2004; Nygren et al., 2004; for
review, see Murry et al., 2005). Furthermore, clear demonstration
of long-term beneficial effects of these cell-based therapies has
been elusive (Chien, 2006b; Rosenzweig, 2006). For example,
the most recent series of studies suggest that bone marrow cells
may improve the function of infarcted myocardium mainly by
promoting angiogenesis or cell survival, without cardiac muscle
regeneration (Fazel et al., 2006, 2007; for review, see Chien,
2004, 2006a; Wu et al., 2008).
Concurrent with the work discussed above, several studies of
putative heart stem cells and progenitors that are resident in the
postnatal or adult heart have been reported (Beltrami et al., 2003;
Laugwitz et al., 2005; Martin et al., 2004; Messina et al., 2004; Oh
et al., 2003) (reviewed in Evans et al., 2007; Laugwitz et al., 2008;
Parmacek and Epstein, 2005; Wu et al., 2008). In these studies of
resident heart cells, cell surface markers that identify stem cell
populations in other tissues have been utilized to isolate cells
from the adult heart, with the hope of identifying putative progen-
itors. These candidates were also subjected to long-term culture
and their ability to generate progeny with a cardiac phenotype
was scored during long-term culture, as outlined in Figure 3.
Using this strategy, Anversa and colleagues identified a line-
age-negative, c-kit-positive (Lin, c-kit+) population in the adult
rat (Beltrami et al., 2003). This population was reported to be
clonogenic, self-renewing, and multipotent, able to differentiate
into cardiomyocytes, smooth muscle, and endothelial cells. Of
note, these c-kit+ cells have been shown recently to differentiate
into smooth muscle and endothelial cells after engraftment,
becoming part of the coronary arterial tree in infarcted hearts
(Tillmanns et al., 2008). Similarly, Schneider’s group isolated
Sca-1-positive adult mouse cardiac stem cells that could differ-
entiate into cardiomyocytes after 4 weeks of treatment with the
chemical demethylation agent 50-azacytidine (Oh et al., 2003),
although the self-renewal and clonogenic potential of the cells
remain undetermined. Using a different approach, Garry and
coworkers described a subset of Sca-1-positive cells, named
side population cells based on their dye exclusion properties,
which express an ATP-binding cassette transporter (ABCG2).
These cells can differentiate into cardiomyocytes by coculture
with bulk populations of cardiac cells (Martin et al., 2004), while
their clonogenic potential, self-renewal capacity, developmental
origin, and the phenotypic characteristics of the differentiated
cardiomyocytes remain to be determined. Concomitantly,
another group described a mixed population of cells called
‘‘cardiosphere cells’’ (CSs) derived from human cardiac biop-
sies. CSs are c-kit, Sca-1, and Flk-1 positive and can self-renew
and differentiate into cardiomyocytes by coculture with postna-
tal rat cardiomyocytes (Messina et al., 2004). Subsequently,
modifications to the original protocol described by Messina
et al. have been reported to improve the efficiency of the cardio-
sphere cultures, and to obtain sufficient cell numbers for trans-
plantation (Smith et al., 2007). Because many of these markers
identify a diverse group of cells outside of the heart, many of
which traverse the heart, or are resident but clearly not endoge-
nous cardiac stem cells (e.g., monocytes, macrophages, or
blood derivatives) (Massberg et al., 2007; Pouly et al., 2008), it
is essential to define additional criteria to identify the subset of
the c-kit+ Sca-1+ Flk-1+ population that exhibits cardiac progen-
itor activity. For example, it would be extremely interesting to
determine the relationship between bone marrow and cardiac
c-kit-positive stem cells.
Finally, in order to validate any claim that a given cardiac-
derived cell functions as an endogenous stem or progenitor
cell, in vivo verification via lineage tracing in the absence of
transplantation is ultimately required. Even though short-term
improvement of cardiac function has been reported after injec-
tion of some of these populations into normal or infarcted myo-
cardium (Beltrami et al., 2003; Messina et al., 2004; Oh et al.,2003), the unequivocal contribution to cardiomyocyte regenera-
tion is not yet definitive. Attempts to address this point have been
confusing due to instances of observed cell fusion, as reported
for the Sca-1 population (Oh et al., 2003), that can lead to false
positive results. Additionally, the possibility that the reported
functional improvement is due to the release of prosurvival or an-
giogenic factors as a secondary effect of the injection of trans-
planted cells, as observed in some studies with bone marrow
(Fazel et al., 2006, 2007; Meyer et al., 2006), cannot be ruled
out. Moreover, because many of these studies use mixed popu-
lations as a starting material, clonal assays and lineage-tracing
experiments are critical to rule out that any cells of extracardiac
origin gave rise to the putative cardiac stem cells. Obviously,
a new set of rigorous criteria need to be established to allow
the unequivocal and reproducible identification, purification, ex-
pansion, and directed differentiation of any potential heart stem
cell or cardiac progenitor.
Shortly after the above-mentioned cardiac stem cells were
reported, we demonstrated the existence of a postnatal cardiac
progenitor population marked by the expression of the LIM
homeodomain transcription factor Isl1 (Laugwitz et al., 2005).
Postnatal isl1+ progenitors can differentiate into functionally fully
mature cardiomyocytes (confirmed by electrophysiological
experiments and positive immunostaining for cardiac markers)
by coculture with neonatal cardiomyocytes. More importantly,
isl1 expression labels progenitors in the second heart field and
its derivatives, as demonstrated by lineage-tracing analysis
(Cai et al., 2003; Moretti et al., 2006; Sun et al., 2007), providing
evidence that isl1marks progenitors with cardiac origin. Interest-
ingly, an embryonic multipotent isl1+ cardiovascular progenitor,
able to give rise to the major three cell types of the heart (cardi-
omyocytes, smooth muscle, and endothelial cells), and with
clonogenic and self-renewing ability, has been recently identified
in vivo and in vitro (Moretti et al., 2006). While further in vivo
transplantation experiments need to be done to evaluate the
regeneration potential of the postnatal isl1+ progenitors, the de-
velopmental connection between the embryonic and postnatal
isl1+ populations positions these progenitors as attractive candi-
dates for cardiac stem cells.
Whether some of the proposed heart stem cells discussed
above represent different subsets of a common progenitor
pool, or whether these populations partially overlap at certain
cardiac developmental stages remains unclear. Understanding
the potential relationship between these populations will be im-
portant to clarify the existence of a genuine pool of postnatal
resident cardiac stem cells (see Figure 3 for a list of potential
heart stem cells and their known phenotypic characteristics).
Lives of a Heart Muscle Cell: Precursors, Progenitors,
Intermediates, Neonatal, and Adult
Cell therapies for heart disease require regenerating a diverse
array of cardiac cells, and one major focus in current cell-based
therapy is to regenerate heart muscle cells, whose loss of func-
tion ultimately leads to heart failure. During development, heart
muscle cells acquire the fully differentiated adult phenotype via
a series of spatially and temporally controlled maturational steps
(Sedmera et al., 2000) (Figure 4). For the most part, these cells
are derived from progenitors of both the first and second heart
fields (Buckingham et al., 2005). In the early heart tube, the newlyCell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 321
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ReviewFigure 1. Properties of Skeletal Muscle and Bone Marrow Populations Analyzed for Cardiac Regeneration
This table summarizes the results of multiple studies of skeletal muscle- and bone marrow-derived populations that have been isolated and manipulated to
assess their potential to give rise to cells with cardiac phenotype and/or function. One or more representative reports for each tissue source are shown. Individual
populations isolated from a single tissue are distinguished by blue, red, or black text within a given column. For cases in which cardiac improvement was assayed
in vivo, the time point of analysis is indicated as weeks postinjection (p.i) in the ‘‘Functional Properties after Manipulation’’ row.
Asterisk (*), cell fusion between transplanted hematopoietic bone marrow-derived stem cells and recipient cardiomyocytes has been reported (Murry et al., 2005).
#, arrythmia after skeletal muscle transplantation in patients with severe ischemic cardiomyopathy has been reported (Menasche, 2003). §, paracrine factors
promoting cell survival and/or angiogenesis rather than real cellular contribution may be responsible for the functional improvement reported after bone marrow
stem cell injection in the infarcted myocardium (Fazel et al., 2006).formed ventricular muscle cells are poorly striated, with few
organized sarcomeres, and a composition of voltage-gated
channels consistent with an immature electrophysiological322 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.phenotype. As the looping heart tube continues into a four-
chambered structure, there is a marked expansion in the thick-
ness of the ventricular chamber wall. This change reflects the
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ReviewFigure 2. Properties of Extracardiac Tissue Populations Analyzed for Cardiac Regeneration
This table summarizes the results of multiple studies of extracardiac tissue-derived populations that have been isolated and manipulated to assess their potential
to give rise to cells with cardiomyocyte phenotype and/or function. Significant reports are indicated for each tissue source. Individual populations isolated from
a single tissue are distinguished by blue, red, or black text within a given column. Abbreviations used are as follows: SM, smooth muscle; MI, myocardial infarc-
tion; and EB, embryoid bodies.expansion of the compact zone (Figure 4A), which contains the
cells that represent the most proliferative cardiac myocytes in
the mammalian heart. A subset of these cells migrates out
toward the interior of the chamber to form trabecular, finger-
like structures. Trabeculation increases the myocardial surface
for a proper oxygenation in the absence of an intact coronary
circulation. These cells are more differentiated, showing an
increased sarcomeric organization and a lower mitotic rate (Har-
vey, 2002; Wessels and Sedmera, 2003). Even after birth, the
neonatal cardiomyocyte does not have a fully developed sarco-meric/cytoskeletal network, and lacks mature Z disks, T tubules,
and extensive sarcoplasmic reticular membrane structures.
After several weeks, the ventricular muscle acquires the charac-
teristic rod-shaped structure, with fully formed intercalated discs
and extensive components of the calcium cycling proteins,
which are required to maintain adult contractile function. Given
these discrete steps, it is becoming increasingly clear that for
ES-derived cardiomyocytes to live up to their therapeutic poten-
tial and promote cardiac contractility in the failing heart, it will be
critical to direct them to a fully mature phenotype.Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 323
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ReviewFigure 3. Characteristics of Resident Cardiac Progenitors and Stem Cells
This table summarizes the results of multiple studies that examined the phenotype and functional traits of putative endogenous cardiac stem and progenitor
populations. (a) Laugwitz et al., 2005; (b) Oh et al., 2003; (c) Beltrami et al., 2003; (d) Martin et al., 2004; (e) Messina et al., 2004.
#, Wnt/b-catenin pathway involved in self-renewal of isl1+ progenitors (Qyang et al., 2007). Asterisk (*), clonality determined for embryonic isl1+ progenitors in vivo
and in vitro (Moretti et al., 2006).H, cell fusion detected (Oh et al., 2003). U, cardiomyocytes show a mature phenotype and properties after in vivo injection but
not in in vitro differentiation assays (Beltrami et al., 2003). {, c-Kit cells in the heart may include circulating monocytes (Massberg et al., 2007; Pouly et al., 2008).J,
a-SMA has been reported as an early transient marker during cardiomyogenesis. Abbreviations: CM, cardiomyocytes; SM, smooth muscle; E, endothelial; SkM,
skeletal muscle; Bd, blood; CV, cardiovascular; and p.i, postinjection.Some members of the T box family have been reported to be
important in the ventricular trabeculation process, e.g., Tbx-5
and Tbx-20, which promote myocardial chamber specification,324 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.while Tbx-2 and Tbx-3 function as antagonists and inhibit cham-
ber formation (Dunwoodie, 2007; Hoogaars et al., 2007). How-
ever, relatively little is known about the detailed molecular
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Reviewpathways that drive specific steps of later ventricular maturation
(Christoffels et al., 2004; Wagner and Siddiqui, 2007). One of the
genes involved in the regulation of ventricular trabeculation is
neuregulin-1 (NRG1), which is released from the endocardium
and recognized by myocardial ErbB2/ErbB4 receptors, stimulat-
ing myocardial cells to proliferate and migrate to the emerging
trabeculae (Gassmann et al., 1995; Lee et al., 1995; Meyer and
Birchmeier, 1995). BMP-10 has been reported as a key regulator
of myocardium proliferation and postnatal hypertrophic growth,
essential to the ultimate formation of adult compact myocardium
(Chen et al., 2004, 2006; Pashmforoush et al., 2004). The retinoic
acid signaling pathway has been implicated in the formation of
the trabeculated myocardium as well (reviewed in Wagner and
Siddiqui, 2007). Interestingly, Grego-Bessa et al. have recently
reported an essential role for Notch signaling during ventricular
chamber formation, not only in modulating the expression levels
of some genes involved in ventricular maturation, as observed
for BMP-10 or NRG1, but also in regulating cardiomyocyte pro-
liferation and differentiation (Grego-Bessa et al., 2007).
Development of single-cell assays using FACS-purified sub-
sets should eventually allow the identification of discrete inter-
mediates of cardiac myocyte maturation process. Because it is
difficult to obtain a substantial amount of homogeneously
mature cardiac muscle cells from ES cell sources (Mummery,
2007), it may be more productive to develop the means to purify
the ES cell equivalent of precommitted embryonic compact zone
ventricular cardiomyocytes (Figure 4). Such purified progenitors
may then be used to explore the pathways required for their
maturation into fully adult rod-shaped cardiomyocytes. Similar
approaches should apply to other heart cell types (i.e., endothe-
lial or smooth muscle cells), even though they may not undergo
similarly sophisticated maturation steps.
Hunting for Endogenous Heart Progenitors
via Lineage Tracing
In vivo genetic marking to track the fate of specific cell types of
interest has increasingly become a gold standard in the identifi-
cation of novel stem cells and related progenitors. Recent
advances in conditional gene targeting and the identification of
tissue-specific enhancer/promoters have allowed the irrevers-
ible genetic tagging of a given cell type at almost any stage of
fetal, neonatal, and adult cardiovascular development. This
approach enables direct tracking of the conversion of the cell
of interest to other intermediates or fully differentiated progeny
in the context of the intact heart in situ, without the need for direct
injection or transplantation (Dodou et al., 2004; Laugwitz et al.,
2005; Moretti et al., 2006). In this manner one can trace a given
subset of cells at various stages, and at the same time determine
the effects of gain or loss of function of specific genes on the fate
of the cell of interest. The ability to temporally control the expres-
sion of putative molecular switches also allows a clear determi-
nation of whether specific steps in the directed differentiation of
a given heart progenitor are indeed irreversible, an important
point that is directly related to the regenerative potential of spe-
cific heart progenitor subsets. If the reporter is fluorescent, the
isolation of the cells from intact tissue at either embryonic or
postnatal stage is possible, allowing direct comparison of
changes in the progenitor pool over time, an important point as
it appears that the multipotency of a given progenitor subsetchanges during fetal heart development and becomes progres-
sively more restricted. Multicolor reporters are on the horizon
and should allow for discrimination of the relationships between
progenitors that become committed to distinct heart cell line-
ages (conduction, endothelial, atrial, ventricle, smooth muscle,
etc.) in specific heart components (aorta, coronary artery,
pulmonary artery, etc.). Finally, the ability to conditionally induce
injury and to subsequently monitor the mobilization of certain
progenitor subsets at particular stages of embryonic and adult
development will be a powerful tool. The use of this approach
may help to resolve several of the controversial published find-
ings that have largely relied on in vitro expansion of mixed pools
of putative progenitors, followed by their in vivo injection into the
postinfarcted heart that represents a very complex cellular
milieu.
Multipotent Cardiovascular Progenitors and Lineage
Diversification in the Heart
As noted above, the heart is composed of diverse cell types: car-
diac muscle, smooth muscle, conduction system, endothelial,
valvular, and interstitial mesenchymal fibroblast cells. A further
level of complexity is found in the distinct phenotypic differences
present in these cell types at separate regions of the heart. For
example, the smooth muscle cells in the pulmonary artery, aorta,
and coronary arterial system have unique physiological re-
sponses to external hormonal and environmental stimuli (Maje-
sky, 2007), such as adrenergic agonists, hypoxia, and elevated
blood pressure. Conduction system myocytes exhibit signature
action potentials depending upon their location, whether it be
the pacemaker cells in the sinoatrial node, the atrioventricular
node (located at the intersection of the atrial and ventricular
chambers), or the distal Purkinje system that transmits electrical
impulses directly to the ventricular chambers (Gourdie et al.,
2004). An increasing body of evidence suggests that there may
be a common cardiovascular progenitor in the early first and sec-
ond heart fields (Abu-Issa et al., 2004; Buckingham et al., 2005).
More recent studies suggest that lineage diversity is, to a large
extent, generated by the presence of mesodermally derived,
multipotent cardiovascular progenitors (Kattman et al., 2006;
Moretti et al., 2006; Wu et al., 2006). As discussed in the first sec-
tion of this review, isl1+ progenitors in the second heart field
differentiate into several cardiac lineages and give rise to over
two-thirds of the cells in the heart, mostly on the right side, in-
cluding most of the conduction system, proximal coronary arte-
rial tree, atrial and right ventricular chambers, and outflow tract
myocardium (Cai et al., 2003; Laugwitz et al., 2005; Moretti
et al., 2006; Sun et al., 2007). The initial steps in the generation
of this diversity appear to be due to fate decisions at the sin-
gle-cell level, indicating the presence of a multipotent isl1+ car-
diovascular progenitor. Recent studies show the isolation of
these cells from both murine ES cells and early-stage embryos
(Moretti et al., 2006), suggesting the potential importance of
extending similar work to human ES cells in order to generate
specific ‘‘heart tissues’’ for cardiovascular regenerative medi-
cine. In addition, it will be critical to obtain a more comprehensive
cell fate map for these multipotent progenitors and their down-
stream derivatives, as well as to determine the specific signals
that drive discrete decisions to form differentiated progeny of
interest (Figure 5). The identification of additional molecularCell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 325
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ReviewFigure 4. Ventricular Cardiomyocyte Formation and Maturation
Major steps in ventricular chamber myocyte maturation are displayed graphically at the level of tissue structure (A), or at the single cell level (B). The migration and
fusion of progenitors from the first heart field and second heart field of the cardiac crescent lead to heart tube formation (E7.5–8.5) (Buckingham et al., 2005;
Harvey, 2002). The looping heart tube (E8.5–E10) consists of an outer layer of myocardium (pink round-shape cells) and an inner layer of endocardium (gray)
separated by the cardiac jelly matrix (pink) (Moorman and Christoffels, 2003). The ventricular cardiomyocytes from the myocardial layer proliferate into three
or four layers and form the compact zone (red square-shape cells) at around E10.5, which is a rapid proliferative stage of cardiac myogenesis. Meanwhile, an
epicardial layer envelops the heart from migrating proepicardial organ cells (green) (Winter and Gittenberger-de Groot, 2007). Continued proliferation, differen-
tiation, and migration of the inner layer myocardium result in the trabeculated cardiomyocytes (orange) inside the lumen of the ventricles (E12), which have
a slower proliferative rate and show more organized sarcomeric structure (Wessels and Sedmera, 2003). These cells undergo trabecular compaction at later
embryonic stages before turning into the more matured neonatal cardiomyocytes. Only until several weeks after birth do the ventricular cardiomyocytes acquire
the characteristic rod-shaped structure with intercalated discs. See Sedmera et al. (2000) for more detail.pathways and the potential existence of cell surface markers that
can identify specific subsets in the isl1+ hierarchy of progenitors
will be extremely valuable. Toward this end, the recent discovery
of a powerful Wnt/b-catenin renewal system for the multipotent
and bipotent isl1+ progenitors (Qyang et al., 2007) may eventu-
ally lead to the cloning of these intermediates from murine and
human ES cells or tissue sources.
Relatively less is known about the first heart field precursors,
which give rise to much of the left ventricular chamber (Bucking-
ham et al., 2005). This largely reflects the lack of specific markers
for this cell population. It will be interesting to compare the prop-
erties of first heart field progenitors with multipotent isl1+ pro-
genitors, in order to elucidate the relationship between these dif-
ferent lineages, as well as their respective progenies which
remain poorly understood (Figure 5). Before this can be accom-
plished, it must also be determined whether the progenitors from
the first heart field can also persist in the postnatal heart, as do
isl1+ progenitors. These second heart field progenitors play an
important role in the maturation of the conduction system (Mor-
etti et al., 2006; Sun et al., 2007), and any malfunction in this pool
of cells during development could result in congenital heart dis-
ease such as defects in the atrial and ventricular septa and out-
flow tract maturation and positioning. When these functions are
completed shortly after birth, the number of isl1+ progenitors
drops off precipitously (Laugwitz et al., 2005). Because the
most common cause of human heart failure occurs due to the
loss of functional muscle cells in the left ventricular chamber, it
will be particularly relevant to determine whether progenitors in
the first heart field persist into late adulthood. Conditional lineage
tracing should be invaluable to assess their potential for mobili-
zation and/or regeneration of cardiac muscle following heart
injury.326 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.Vascular Progenitors outside the Heart Fields:
Endothelial, Neural Crest, and Epicardial Progenitors
Vascular progenitors are found in three distinct embryonic com-
partments. In the heart, endothelial cells are found throughout
the cardiac chambers in the endocardial lining, as well as in all
of the large and small blood vessels. In contrast to the clear
role of blood-derived hemangioblasts in endothelial formation
of extracardiac vasculature, recent lineage-tracing studies indi-
cate a distinct origin for the endothelial cells in the heart, largely
derived from isl1+ heart progenitors in the second heart field
(Moretti et al., 2006; Sun et al., 2007). Putative circulating endo-
thelial progenitors have been described, but they appear to have
overlapping features, both functionally and in their transcrip-
tional profiles, with circulating monocytes (Grunewald et al.,
2006). In addition, there is currently no direct evidence to indi-
cate the contribution of this circulating population to endothelial
lineages in vivo by lineage tracing. Migrating cardiac neural crest
(CNC) lineage cells contribute significantly to the smooth muscle
layer in the outflow tract (OFT), and are involved in the formation
of the aorticopulmonary septum, as demonstrated by rigorous
lineage-tracing studies using well-characterized neural crest-re-
stricted Cre mouse lines (Echelard et al., 1994; Jiang et al., 2000;
Li et al., 1999, 2000). The characterization of potential vascular
progenitors derived from CNC cells and their function in cardiac
injury remain to be determined (Snider et al., 2007).
One of the most interesting new subsets of vascular progeni-
tors is derived from the proepicardial organ (PEO), which ulti-
mately gives rise to components of the coronary arterial tree, in-
terstitial cells and the microvasculature. The PEO is an epithelial
layer associated with the septum transversum. Free-floating ag-
gregates of epicardial cells from the PEO migrate through the
pericardial cavity to the heart and then envelop it to form the
Cell Stem Cell
ReviewFigure 5. A Working Model of Heart Cell Lineage Diversification with a Proposed Cellular Hierarchy from Multipotent Mesodermal
Progenitors
This provisional schematic fate map of cardiac progenitors is based on currently available data and integrates work from mouse ES cells with in vivo lineage-
tracing results. We propose that a yet to be defined common primordial cardiovascular progenitor population (inside the dashed box) derived from Bry+ meso-
dermal precursors gives rise to both first and second heart field progenitors (for review see Buckingham et al. (2005). The Bry+ precursors may differentiate early
during development (EB day 3.25) into Bry+, Flk-1+ hemangioblasts and, after a second wave of Flk-1 expression (EB day 4.25), into cardiac mesodermal pre-
cursors (U) (Kattman et al., 2006). Whether the common primordial cardiovascular progenitor cells (c) are derived from the latter awaits further investigation.
Within the second heart field, Isl1, together with Nkx2.5 and Flk-1, defines multipotent isl1+ cardiovascular progenitor cells (MICPs, q), which can give rise to car-
diomyocytes, smooth muscle cells, and endothelial cells, representing all three major cell lineages of the heart (Moretti et al., 2006). A specific subset of precur-
sors derived from the MICPs may function as bipotent progenitors, restricting their downstream progenies to smooth muscle and endothelial cells or smooth
muscle and cardiomyocytes. Nkx2.5 bipotent progenitors (p) may account for cardiomyocytes and/or smooth muscle cells of both heart fields (Wu et al.,
2006), although the exact relationship with MICPs remains to be determined. The transient intermediates that connect the bipotent progenitors to the differen-
tiated progeny remain unknown, but some second heart field intermediates begin to be elucidated (#) (Qyang et al., 2007; Sun et al., 2007). Additional candidate
genes (shown here with red question marks) that may designate alternate transitional populations await further characterization. Intriguingly, Wnt/b-catenin sig-
naling (v) has been reported to play a critical role in specification, self-renewal, and differentiation of isl1+ progenitors (Qyang et al., 2007), which is consistent with
a number of other reports showing that this pathway expands the second heart field or its derivatives (Ai et al., 2007; Cohen et al., 2007; Kwon et al., 2007; Lin
et al., 2007; Ueno et al., 2007) (for review, see Tzahor, 2007). Other signals repressing the expansion of second heart field progenitors, such as Bmp-2/Smad-1 (z),
have been recently reported (Prall et al., 2007). Proposed, as yet unpublished lineage relationships and transitional populations are indicated with broken arrows
and red question marks. Asterisk (*), second heart field progenitors have also been shown to contribute to the left atrial and, more rarely, left ventricular cardi-
omyocytes (Cai et al., 2003). Abbreviations: Bry, brachyury; Flk-1, fetal liver kinase 1 (VEGF receptor-2); Mesp-1, mesoderm posterior 1; Isl-1, ISL1 transcription
factor, LIM/homeodomain; Nkx 2.5, NK2 transcription factor related, locus 5; SMA, smooth muscle actin; cTnT, cardiac TroponinT; SLN, sarcolipin; Tbx5, T box 5;
SM-MHC, smooth muscle myosin heavy chain; Mlc2-v, ventricular myosin light chain 2; Mlc2-a, atrial myosin light chain 2; MHC, myosin heavy chain; HCN4,
hyperpolarization-activated, cyclic nucleotide-gated K+ 4; CD31 (PECAM 1), platelet/endothelial cell adhesion molecule; and vWf, von Willebrand factor.primitive epicardium (see Figure 6). The proper development of
the PEO and subsequent coronary vasculature depends on sig-
nals not only from the PEO and epicardial cells, but also from the
liver bud, myocardium, and perhaps the endocardium and neural
crest cells (Ishii et al., 2007; Mu et al., 2005; Reese et al., 2002;
Winter and Gittenberger-de Groot, 2007). Under defined condi-tions, adult epicardial cells derived from mouse, rat, and human
can undergo an epithelial to mesenchymal transition (EMT) to
produce smooth muscle cells of the coronary vessels as well
as the surrounding fibroblast of the adventitia (Smart et al.,
2007; van Tuyn et al., 2007; Wada et al., 2003). However, no con-
sensus has been established regarding the origin of coronaryCell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 327
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ReviewFigure 6. Epicardium Formation and Model of the Contribution of the Epicardial Progenitors to the Coronary Vessels
Cell aggregates from the PEO migrate and envelop the heart tube to form the epicardial layer at around E10.5 (right panel). Epicardial cells then proliferate,
undergo EMT, and migrate to the upper layers of the compact zone (red square-shape cells) and trabecular myocardium (orange cells) to form the coronary ves-
sels (red, blue, and purple cells) and interstitial fibroblast (purple cells) (left and middle panels). Signals derived from the epicardium, the myocardium, and maybe
even the endocardium are required for coronary arteriogenesis. Only some representative signaling pathways are shown here (Bhattacharya et al., 2006; Merki
et al., 2005; Smart et al., 2007; Winter and Gittenberger-de Groot, 2007) (middle panel). The CNC cells start migrating from the dorsal neural tube to the OFT
through the pharyngeal arches as early as E10.5, and contribute mainly to the smooth muscle layer in the OFT. Note that the subepicardial space is dispropor-
tionally enlarged. EMT, endothelial-mesenchymal transition; PEO, proepicardial organ; NT, neural tube; AAA, aortic arch arteries; AS, aortic sac; OFT, outflow
tract; RV, right ventricle; LV, left ventricle; AV, atrioventricular septum; RA, right atrium; LA, left atrium; and CNC, cardiac neural crest.endothelial cells (Lie-Venema et al., 2007; Winter and Gitten-
berger-de Groot, 2007). Additionally, as mentioned above, isl1+
progenitors from the second heart field also give rise to endothe-
lial cells of the coronary tree, as shown by lineage-tracing exper-
iments (Moretti et al., 2006; Sun et al., 2007). Therefore, future
experiments employing lineage tracing with epicardial restricted
genetic markers will be required to clarify the potential contribu-
tion of epicardial cells to the coronary endothelium.
The epicardium is essential for the maintenance of myocardial
architecture, as interstitial fibroblasts derived from epicardial-
derived cells (EPDCs) physically support the surrounding cardi-
omyocytes and comprise a significant proportion of the myocar-
dial wall. In addition, several epicardial-secreted factors have
been reported to play a critical role in the proliferation and/or
maturation of the myocardium, such as retinoic acid and FGFs
(see Figure 6). These observations are supported by experimen-
tal results showing a thin ventricular myocardium phenotype af-
ter physical or genetic ablation of the epicardium (for review, see
Lie-Venema et al., 2007). Whether the proepicardial progenitors
directly differentiate into cardiac muscle cells is not entirely clear
(Kruithof et al., 2006) but is under active investigation.
Intriguingly, recent studies have suggested that the proepicar-
dial progenitor population can be mobilized after cardiac injury,
and discrete signals such as retinoic acid, FGF, and Thymosin
b4, as well as the transcription factor TBX-18, which are also in-
volved in PEO and coronary development, have been reported to328 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.trigger this response (Lepilina et al., 2006; Smart et al., 2007),
suggesting potential paracrine, non-cell-autonomous pathways
to drive neoangiogenesis following cardiac injury. Therefore,
epicardial progenitors are positioned as an attractive target for
future research, as they may play a critical role in heart develop-
ment by contributing to several cardiac cell types. However,
definitive lineage-tracing experiments may be required to probe
the real contribution of EPDCs to different heart components.
Understanding the developmental relationship between proepi-
cardial progenitors and those of the cardiac heart fields will be
relevant and very valuable information. Therefore, one can envi-
sion a potential cardiac cell therapy employing both heart field-
derived and proepicardial-derived progenitors. Alternatively,
various differentiated progeny may be harnessed, as these pop-
ulations may provide not only a source of muscle cells, but also
the precursors of cells for coronary vessel formation, and inter-
stitial fibroblasts that act as supporting scaffold cells.
The Road Ahead: Life, Death, and Rebirth
of Human Heart Cells
Collectively, heart cells are the unitary elements of human
cardiac disease. The discovery of a myriad of distinct heart pro-
genitors in murine embryos and ES cell systems is building
a foundation for parallel studies in human ES cells. Future studies
will be aimed at developing a human cardiovascular cell lineage
fate map, complete with the molecular markers to identify and
Cell Stem Cell
Reviewpurify the cellular hierarchy, and with signaling pathways that
direct discrete steps of renewal and conversion to distinct differ-
entiated progeny. The vast majority of clinically important cardio-
vascular disease during aging results from the death of heart
cells (discussed in Chien and Karsenty [2005]). Via studies of
human ES cells, a rebirth of human heart cells is likely to be on
the horizon.
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